Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
The genetic underpinnings of Alzheimer's disease (AD) remain largely elusive despite early successes in identifying three genes that cause early-onset familial AD (those that encode amyloid precursor protein (APP) and the presenilins (PSEN1 and PSEN2)), and one genetic risk factor for late-onset AD (the gene that encodes apolipoprotein E (APOE)). A large number of studies that aimed to help uncover the remaining disease-related loci have been published in recent decades, collectively proposing or refuting the involvement of over 500 different gene candidates. Systematic meta-analyses of these studies currently highlight more than 20 loci that have modest but significant effects on AD risk. This Review discusses the putative pathogenetic roles and common biochemical pathways of some of the most genetically and biologically compelling of these potential AD risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ε4 allele of the apolipoprotein E (APOE) gene is the major genetic risk factor for AD and dementia with Lewy bodies (DLB) (1, 5, 6), whereas APOE2, a well-established longevity determinant, affords protection against the disease (7, 8).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [1]
In the citing paper
“Familial Alzheimer’s disease, which has an autosomal dominant form of inheritance and early onset, has been associated with mutations in APP, PSEN1 and PSEN2, three genes that are critical for beta amyloid (Aβ) production61.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [61]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P. A., & Hirschhorn, J. N. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2344 · Cited by 2,891
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“Despite the lack of MAPT mutations in AD, it is likely that tau dysfunction still contributes to AD ris”
BackgroundRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“, none of these candidates has been proved to consistently influence disease risk or onset age in more than a handful of sample”
BackgroundSelf-citation
Research works printed but not linked: 1
- Meyer, J. M. & Breitner, J. C. Multiple threshold model for the onset of Alzheimer's disease in the NAS-NRC twin panel. Am. J. Med. Genet. 81, 92–97 (1998). · DOI · Paper page
Cited by
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
“Mutations in three genes—amyloid precursor protein, presenilin 1, and presenilin 2—cause an early onset, autosomal dominantly inherited AD [17].”
BackgroundSuper-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662
“Alzheimer’s disease is a common form of dementia characterized by progressive neurodegeneration and loss of cognitive functions of the brain, and much of the genetic variation implicated in Alzheimer’s disease is associated with amyloid precursor protein, transmembrane proteins, and apolipoprotein E4 (Bertram and Tanz…”
Mechanisms underlying inflammation in neurodegeneration
Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580
“Rare mutations in APP and the presenilin components of g-secretase are causes of familial AD, providing one line of evidence for the hypothesis that Ab contributes to the pathogenesis of AD (Bertram and Tanzi, 2008).”
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
“For example, familial Alzheimer’s Disease (AD) patients commonly have mutations in the amyloid precursor protein or presenilin genes which lead to the production and deposition in the brain of increased amounts of the Abeta peptide, characteristic of AD (Bertram and Tanzi, 2008).”
BackgroundThe Pathobiology of Vascular Dementia
Iadecola, C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.008 · Cited by 1,857
“Shortly after, mutations in the amyloid precursor protein (APP) gene were identified in familial forms of AD (Bertram and Tanzi, 2008).”
Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651
Dendritic spine pathology in neuropsychiatric disorders
Penzes, P., Cahill, M. E., Jones, K. A., VanLeeuwen, J.-E., & Woolfrey, K. M. (2011) · Nature Neuroscience · doi:10.1038/nn.2741 · Cited by 1,523
Genetic architectures of psychiatric disorders: the emerging picture and its implications
Sullivan, P. F., Daly, M. J., & O'Donovan, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3240 · Cited by 1,177
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
“Individuals with one e4 allele are three to four times as likely to develop AD than those without e4 allele”
BackgroundAlzheimer's disease: strategies for disease modification
Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,064
“Of all the possible genetic causes of AD, e4 is the one involved in most case”
BackgroundClinical epidemiology of Alzheimer’s disease: assessing sex and gender differences
Mielke, M., Vemuri, P., & Rocca, W. (2014) · Clinical Epidemiology · doi:10.2147/clep.s37929 · Cited by 1,021
“Compared to non-carriers, heterozygous carriers of one ε4 allele are 3–4 times more likely to develop AD, whereas the risk for homozygous carriers is even higher.(87,88) The APOE ε4 allele is specifically associated with an earlier age of onset of AD.”
Linking lipids to Alzheimer's disease: cholesterol and beyond
Di Paolo, G., & Kim, T.-W. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3012 · Cited by 972
Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease
Bell, R. D., & Zlokovic, B. V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0522-3 · Cited by 860
“Ab (38–43 amino acids) is a proteolytic by-product from the amyloid precursor protein (APP) generated by the sequential b-secretase and c-secretase cleavage.”
BackgroundInfluentialThe Genetics of Alzheimer Disease: Back to the Future
Bertram, L., Lill, C. M., & Tanzi, R. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.013 · Cited by 834
“The outcomes have been inconsistent; of the nearly 700 candidate AD genes investigated over the past 30 years, only few show significant risk effects when data from all available studies are combined (Bertram and Tanzi, 2008) (for an up-to-date overview see the AlzGene Database).”
BackgroundInfluentialSelf-citationThe Genetics of Alzheimer's Disease
Bertram, L., & Tanzi, R. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00008-4 · Cited by 760
Self-citationAdvances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
“Diseases such as cancer [2], Parkinson’s [3], rheumatoid arthritis [4], and Alzheimer’s [5] have all had many of their genetic components revealed, bringing us closer than ever to ‘personalized medicine’ [6].”
BackgroundWang, C., & Holtzman, D. M. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0478-5 · Cited by 615
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
“The APP gene is located on chromosome 21 and those individuals suffer from Down's syndrome (trisomy 21) with an extra copy of this chromosome develops an early-onset familial AD (EOFAD) (Yoshikai et al., 1990; Ling et al., 2003).”
InfluentialAstrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer’s disease
Singh, D. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02565-0 · Cited by 569
“Mutation in APP and γ-secretase components presenilin 1 and 2 causes rare familial AD [75].”
BackgroundOxidative stress in neurodegenerative diseases.
Chen, X., Guo, C., & Kong, J. (2012) · PubMed · doi:10.3969/j.issn.1673-5374.2012.05.009 · Cited by 356
“The main histological features are extracellular protein deposits called senile Aβ-amyloid plaques and intraneuronal neurofibrillary tangles [73] .”
BackgroundDinkins, M. B., Dasgupta, S., Wang, G., Zhu, G., & Bieberich, E. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.012 · Cited by 494
“We chose a strain that expresses 5 familial human APP and PS1 AD mutations (5XFAD) that primarily produce Ab1e42 with plaques forming as early as the age of 2 months (Oakley et al., 2006).”
InfluentialThe circadian clock and pathology of the ageing brain
Kondratova, A. A., & Kondratov, R. V. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3208 · Cited by 482
Dendritic Spines: The Locus of Structural and Functional Plasticity
Sala, C., & Segal, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00012.2013 · Cited by 465
“Mutations in three major genes implicated in beta amyloid (A ) metabolism (APP, PSEN1, and PSEN2) have been associated with familial AD with an autosomal dominant form of inheritance and early onset of the disease (37, 38).”
BackgroundPanula, P., Chen, Y.-C., Priyadarshini, M., Kudo, H., Semenova, S., Sundvik, M., & Sallinen, V. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.010 · Cited by 453
“Alzheimer's disease can be caused by mutations of several genes (Bertram and Tanzi, 2008), which has lent support to involvement of both intra- and extracellular mechanisms of widespread degeneration in cortical and subcortical regions.”
A delicate balance: Iron metabolism and diseases of the brain
Hare, D., Ayton, S., Bush, A., & Lei, P. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00034 · Cited by 443
“In a genome-wide association study (GWAS) study, Tf variant C2 positively correlates with AD risk with an OR of 1.21 (Bertram and Tanzi, 2008), which is supported by a number of independent studies (Van Landeghem et al., 1998; Schjeide et al., 2009; Kauwe et al., 2010) but was not confirmed in a…”
BackgroundInfluentialResting‐state network dysfunction in Alzheimer's disease: A systematic review and meta‐analysis
Badhwar, A., Tam, A., Dansereau, C., Orban, P., Hoffstaedter, F., & Bellec, P. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.03.007 · Cited by 438
“Symptoms usually start after the age of 65, except in the fewer than 5% of patients with early-onset autosomal dominant AD (ADAD) [2].”
InfluentialMolecular Pathogenesis of Alzheimer's Disease: An Update
Sanabria-Castro, A., Alvarado-Echeverría, I., & Monge-Bonilla, C. (2017) · Annals of Neurosciences · doi:10.1159/000464422 · Cited by 418
Jucker, M. (2010) · Nature Medicine · doi:10.1038/nm.2224 · Cited by 401
Białkowska, K., Komorowski, P., Bryszewska, M., & Miłowska, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176225 · Cited by 382
“Aß is generated from amyloid precursor protein (APP) during the process caused by two enzymes, ß-secretase and γ-secretase [62].”
BackgroundIntraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease
Gouras, G. K., Tampellini, D., Takahashi, R. H., & Capetillo-Zarate, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0679-9 · Cited by 372
“Over the past two to three decades significant progress has been made in understanding the genetics, biology and pathology of AD [11, 44, 65, 148].”
Metallostasis in Alzheimer's disease
Ayton, S., Lei, P., & Bush, A. I. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.10.558 · Cited by 352
“Mutations in the hemochromatosis gene (H63D and C82Y; which cause iron retention in peripheral tissues in affected patients), were also found to be associated with AD-risk [222-224], possibly by interacting with the ApoE gene [225-227] to synergistically increase AD risk [218, 228-230].”
BackgroundReducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease
Govindarajan, N., Rao, P., Burkhardt, S., Sananbenesi, F., Schlüter, O. M., Bradke, F., Lu, J., & Fischer, A. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201923 · Cited by 342
Amyloid-β induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer’s disease
Tan, M.-S., Tan, L., Jiang, T., Zhu, X.-C., Wang, H.-F., Jia, C.-D., & Yu, J.-T. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.348 · Cited by 347
“In addition to pyroptosis, NLRP1 inflammasome is responsible for caspase-1-dependent processing of the key proinflammatory cytokine IL-1b to an active secreted form.28,29 And inflammatory mechanisms are also pathogenetic forces in AD.”
BackgroundInfluentialMitochondria, calcium and cell death: A deadly triad in neurodegeneration
Celsi, F., Pizzo, P., Brini, M., Leo, S., Fotino, C., Pinton, P., & Rizzuto, R. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2009.02.021 · Cited by 323
“Mutations in the genes encoding for APP and for Presenilin-1 and -2 (PS1 and PS2), two proteins belonging to the γ-secretase enzymatic complex, have been linked to the familial form of AD (FAD; see [44] for a recent review).”
BackgroundEvaluating historical candidate genes for schizophrenia
Farrell, M. S., Werge, T., Sklar, P., Owen, M. J., Ophoff, R. A., O'Donovan, M. C., Corvin, A., Cichon, S., & Sullivan, P. F. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.16 · Cited by 315
Mosconi, L., Berti, V., Dyke, J., Schelbaum, E., Jett, S., Loughlin, L., Jang, G., Rahman, A., Hristov, H., Pahlajani, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90084-y · Cited by 308
Alzheimer's disease: synapses gone cold
Koffie, R. M., Hyman, B. T., & Spires-Jones, T. L. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-63 · Cited by 308
“Mutations leading to early onset familial AD have been found in the APP gene on chromosome 21q [14], in the presenilin 1 gene (PSEN 1) on chromosome 14q, and the presenilin 2 gene (PSEN 2, a homolog of PSEN 1) located on chromosome 1q [13].”
A Human Stem Cell Model of Early Alzheimer’s Disease Pathology in Down Syndrome
Shi, Y., Kirwan, P., Smith, J., MacLean, G., Orkin, S. H., & Livesey, F. J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003771 · Cited by 310
Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s disease
Frost, S., Kanagasingam, Y., Sohrabi, H., Vignarajan, J., Bourgeat, P., Salvado, O., Villemagne, V, Rowe, C. C., Lance Macaulay, S., Szoeke, C., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.150 · Cited by 297
Testicular Cancer Survivorship: Research Strategies and Recommendations
Travis, L. B., Beard, C., Allan, J. M., Dahl, A. A., Feldman, D. R., Oldenburg, J., Daugaard, G., Kelly, J. L., Dolan, M. E., Hannigan, R., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq216 · Cited by 294
Early versus late onset obsessive–compulsive disorder: Evidence for distinct subtypes
Taylor, S. (2011) · Clinical Psychology Review · doi:10.1016/j.cpr.2011.06.007 · Cited by 292
“For example, early onset Alzheimer's disease is influenced by different genes than the late onset form of the disorder (Bertram & Tanzi, 2008).”
BackgroundThe Nrf2–ARE cytoprotective pathway in astrocytes
Vargas, M. R., & Johnson, J. A. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001094 · Cited by 291
The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE
Guerreiro, R. J., Gustafson, D. R., & Hardy, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.025 · Cited by 285
“As of 16th November 2009 the top 10 results in this database included: APOE (E2/3/4), CLU, PICALM, TNK1, ACE, TFAM, CST3, IL1B, CR1 and CG2039140 (Bertram and Tanzi, 2008).”
Longitudinal MRI atrophy biomarkers: Relationship to conversion in the ADNI cohort
Risacher, S. L., Shen, L., West, J. D., Kim, S., McDonald, B. C., Beckett, L. A., Harvey, D. J., Jack, C. R., Weiner, M. W., & Saykin, A. J. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.029 · Cited by 275
“Genetic variation in the apolipoprotein E gene (APOE) is the most commonly reported genetic risk factor associated with AD, with the presence of a single 4 allele conferring a 2-fold or 3-fold increased risk of developing AD and 2 4 alleles associated with nearly an 11-fold increased risk (Bertram and Tanzi, 2008; Far…”
Song, M., Jin, J., Lim, J.-E., Kou, J., Pattanayak, A., Rehman, J. A., Kim, H.-D., Tahara, K., Lalonde, R., & Fukuchi, K.-I. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-92 · Cited by 273
“Most mutations in the Ab-protein precursor (APP) and presenilin (PS1 and PS2) genes, which are associated with familial AD, increase production of Ab, particularly the 42-amino-acid form of Ab (Ab42) in the brain [1,2].”
VPS35 haploinsufficiency increases Alzheimer’s disease neuropathology
Wen, L., Tang, F.-L., Hong, Y., Luo, S.-W., Wang, C.-L., He, W., Shen, C., Jung, J.-U., Xiong, F., Lee, D.-H., et al. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201105109 · Cited by 270
“Moreover, double mutant mice at 1–2 mo for this event (Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999, 2009; Yan et al., 1999; Tanzi and Bertram, 2005; Bertram and Tanzi, 2008).”
BackgroundApplication of Metabolomics in Alzheimer’s Disease
Wilkins, J. M., & Trushina, E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2017.00719 · Cited by 268
Tan, A., Prasad, R., Lee, C., & Jho, E.-H. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-01028-6 · Cited by 250
“AD is an age-associated neurodegenerative disease characterized by pathological hallmarks of extracellular Aβ plaques and intracellular Tau tangles [76].”
BackgroundProteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery
Bai, B., Vanderwall, D., Li, Y., Wang, X., Poudel, S., Wang, H., Dey, K. K., Chen, P.-C., Yang, K., & Peng, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00474-z · Cited by 257
Genome-wide association studies in Alzheimer’s disease
Bertram, L., & Tanzi, R. E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp406 · Cited by 257
Self-citationPrudencio, M., Hart, P. J., Borchelt, D. R., & Andersen, P. M. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp260 · Cited by 255
“These inherited forms of AD generally show much earlier disease onsets, but disease durations are similar to the sporadic disease (47,48).”
BackgroundHabchi, J., Chia, S., Galvagnion, C., Michaels, T. C. T., Bellaiche, M. M. J., Ruggeri, F. S., Sanguanini, M., Idini, I., Kumita, J. R., Sparr, E., et al. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0031-x · Cited by 249
Dinkins, M. B., Enasko, J., Hernandez, C., Wang, G., Kong, J., Helwa, I., Liu, Y., Terry, A. V., & Bieberich, E. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1429-16.2016 · Cited by 245
“Another hallmark of AD is the accumulation of highly phosphorylated forms of the microtubule-associated protein tau (p-tau), a chief component of neurofibrillary tangles (Bertram and Tanzi, 2008).”
BackgroundNeely, A., Perry, C., Varisli, B., Singh, A. K., Arbneshi, T., Senapati, D., Kalluri, J. R., & Ray, P. C. (2009) · ACS Nano · doi:10.1021/nn900813b · Cited by 244
Mitochondrial dysfunction in neurodegenerative diseases and cancer
de Moura, M. B., dos Santos, L. S., & Van Houten, B. (2010) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20575 · Cited by 243
“[Color figure can be viewed in the online issue, which is available at www.interscience. wiley.com.] for presenilin 1 (PS1) and presenilin 2 (PS2) polypeptides, respectively, both components of the g-secretase complex [Moreira et al., 2006; Bertram and Tanzi, 2008; JakobRoetne and Jacobsen, 2009].”
BackgroundNeurosteroids as regulators of neuroinflammation
Yilmaz, C., Karali, K., Fodelianaki, G., Gravanis, A., Chavakis, T., Charalampopoulos, I., & Alexaki, V. I. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100788 · Cited by 213
“Α significant genetic risk factor for AD is the ε4 allele of the Apolipoprotein E (APOE4) contributing to amyloid β (Aβ) peptide accumulation and increased neuroinflammation (Querfurth and LaFerla, 2010; Newcombe et al., 2018; Bertram and Tanzi, 2008).”
Rossini, P. M., Di Iorio, R., Vecchio, F., Anfossi, M., Babiloni, C., Bozzali, M., Bruni, A. C., Cappa, S. F., Escudero, J., Fraga, F. J., et al. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2020.03.003 · Cited by 233
Circular RNA and Alzheimer’s Disease
Akhter, R. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-1426-1_19 · Cited by 232
Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors
Tayeb, H. O., Yang, H. D., Price, B. H., & Tarazi, F. I. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.002 · Cited by 230
Brain FDG PET and the Diagnosis of Dementia
Shivamurthy, V. K. N., Tahari, A. K., Marcus, C., & Subramaniam, R. M. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.13.12363 · Cited by 227
“APOE ε4 is associated with a dramatically increased risk of neurodegeneration, whereas APOE ε2 is shown to be associated with a decreased risk [35].”
BackgroundApoE-Isoform-Dependent SARS-CoV-2 Neurotropism and Cellular Response
Wang, C., Zhang, M., Garcia, G., Tian, E., Cui, Q., Chen, X., Sun, G., Wang, J., Arumugaswami, V., & Shi, Y. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2020.12.018 · Cited by 223
“ApoE4 is the greatest genetic risk factor for Alzheimer disease (Bertram and Tanzi, 2008).”
Biomarkers of Oxidative Damage and Inflammation in Alzheimer's Disease
Galasko, D., & Montine, T. J. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.89 · Cited by 221
Inflammation in the early stages of neurodegenerative pathology
Khandelwal, P. J., Herman, A. M., & Moussa, C. E.-H. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.07.002 · Cited by 212
“Rare mutations in APP and the presenilin (PS) components of γ-secretase are causes of familial AD, providing one line of evidence that Aβ contributes to the pathogenesis of AD (Bertram and Tanzi, 2008).”
BackgroundMolecular links between Alzheimer’s disease and diabetes mellitus
Yang, Y., & Song, W. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.07.009 · Cited by 201
Strategies for nonviral nanoparticle‐based delivery of CRISPR/Cas9 therapeutics
Chen, F., Alphonse, M., & Liu, Q. (2020) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1609 · Cited by 197
Mild Cognitive Impairment: Diagnosis, Longitudinal Course, and Emerging Treatments
Vega, J. N., & Newhouse, P. A. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0490-8 · Cited by 195
Zhang, C., Browne, A., Child, D., & Tanzi, R. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.133520 · Cited by 189
Self-citationLiu, W., Liu, C., Zhu, J., Shu, P., Yin, B., Gong, Y., Qiang, B., Yuan, J., & Peng, X. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.034 · Cited by 188
“…mice with increasing age may be due in part to the posttranscriptional regulation of miRNAs, we used the prediction algorithms Targetscan (Lewis et al., 2005) (www.targetscan.org) and miRNA.org (Betel et al., 2008; John et al., 2004) (www.microrna.org) to analyze the possible regulators of APP.”
MethodChornenkyy, Y., Wang, W., Wei, A., & Nelson, P. T. (2019) · Brain Pathology · doi:10.1111/bpa.12655 · Cited by 184
“After the discovery that APOE ε4 allele is the strongest genetic risk factor for late onset AD, interest in lipid metabolism gained added momentum (15,32).”
BackgroundAPP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons.
Moore, S., Evans, L. D. B., Andersson, T., Portelius, E., Smith, J., Dias, T. B., Saurat, N., McGlade, A., Kirwan, P., Blennow, K., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.068 · Cited by 179
“The majority of known fAD mutations are autosomal dominant and affect APP or the catalytic components of the g-secretase APP-processing complex, presenilin (PSEN) 1 and 2 (Bertram and Tanzi, 2008).”
Loss of Caveolin-1 Accelerates Neurodegeneration and Aging
Head, B. P., Peart, J. N., Panneerselvam, M., Yokoyama, T., Pearn, M. L., Niesman, I. R., Bonds, J. A., Schilling, J. M., Miyanohara, A., Headrick, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015697 · Cited by 180
“Early-onset AD, which afflicts individuals prior to 60–65 years of age, is known to be caused by mutations in three genes: amyloid precursor protein (APP), presenilin-1, and presenilin-2 [29].”
BackgroundChronic stress as a risk factor for Alzheimer’s disease
Machado, A., Herrera, A. J., de Pablos, R. M., Espinosa-Oliva, A. M., Sarmiento, M., Ayala, A., Venero, J. L., Santiago, M., Villarán, R. F., Delgado-Cortés, M. J., et al. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0035 · Cited by 176
“…AD can be divided into two groups: familiar, with an onset age under 60, which is always produced by the mutation of some specific genes (for a review, see Bertram and Tanzi, 2008), and late onset ( > 60 years old), whose etiology is not yet completely understood, accounting for 95%–98% of cases.”
BackgroundPaulsen, J. S., Nance, M., Kim, J.-I., Carlozzi, N. E., Panegyres, P. K., Erwin, C., Goh, A., McCusker, E., & Williams, J. K. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.08.003 · Cited by 168
Crimins, J. L., Pooler, A., Polydoro, M., Luebke, J. I., & Spires-Jones, T. L. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.03.002 · Cited by 163
“Altered A production is strongly implicated in the initiation of AD by genetic mutations associated with rare familial cases and those cases associated with trisomy 21, which triplicates the precursor of A (amyloid precursor protein) (Bertram and Tanzi, 2008).”
BackgroundUsing zebrafish to assess the impact of drugs on neural development and function
Guo, S. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440902988464 · Cited by 160
Lee, D.-H., Gold, R., & Linker, R. A. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130911783 · Cited by 160
“Loss of neurons in the neocortex, hippocampus and other subcortical regions of the brain are common features of AD [26].”
BackgroundHung, C. O. Y., & Livesey, F. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.095 · Cited by 159
“The majority of known familial AD mutations are autosomal dominant and affect the amyloid precursor protein (APP) gene or the catalytic components of the g-secretase APPprocessing complex, presenilin (PSEN) 1 and 2 (Bertram and Tanzi, 2008).”
BackgroundNeuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection
Risacher, S. L., & Saykin, A. J. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185535 · Cited by 151
“Although APOE is the most significant genetic variant associated with AD (Bertram & Tanzi 2008, Corder et al. 1993), it does not account for all of the AD heritability.”
BackgroundStaszak, M., Staszak, K., Wieszczycka, K., Bajek, A., Roszkowski, K., & Tylkowski, B. (2021) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1568 · Cited by 204
Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
Unzeta, M., Esteban, G., Bolea, I., Fogel, W. A., Ramsay, R. R., Youdim, M. B. H., Tipton, K. F., & Marco-Contelles, J. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00205 · Cited by 144
“Genetic factors have also been linked to higher susceptibility to iron burden in AD (Blázquez et al., 2007; Bertram and Tanzi, 2008; Percy et al., 2008).”
BackgroundSecretase inhibitors and modulators for Alzheimer’s disease treatment
Tomita, T. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.24 · Cited by 146
Ono, K., Condron, M. M., & Teplow, D. B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.086496 · Cited by 145
Hatami, A., Monjazeb, S., Milton, S., & Glabe, C. G. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.755264 · Cited by 144
“Typically, the mutations adjacent to the N terminus of the A sequence lead to an increased production of all A species, whereas the ones near the C terminus lead to an increase in the A 42/A 40 ratio (2, 3).”
BackgroundAlzheimer's disease: the amyloid hypothesis and the Inverse Warburg effect
Demetrius, L. A., Magistretti, P. J., & Pellerin, L. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2014.00522 · Cited by 141
“The reviews by Bertram and Tanzi (2008) as well as Tanzi and Bertram (2005) have elucidated the genetic origins for the familial and the late onset forms of the disease.”
Kocherhans, S., Madhusudan, A., Doehner, J., Breu, K. S., Nitsch, R. M., Fritschy, J.-M., & Knuesel, I. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.0418-10.2010 · Cited by 132
“Combinations of genetic, such as apolipoprotein E (ApoE) 4, and nongenetic risk factors likely determine disease predisposition, age of onset, and progression (Bertram and Tanzi, 2008).”
BackgroundTargeting the JAK2/STAT3 axis in Alzheimer's disease
Chiba, T., Yamada, M., & Aiso, S. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903213426 · Cited by 136
“Genetic analysis has identified three genes that cause early-onset familial AD (FAD) of an autosomal-dominant form [2,3]: amyloid precursor protein (APP), presenilin 1 (PS1) and PS2.”
BackgroundGenetics of Alzheimer's disease: recent advances
Avramopoulos, D. (2009) · Genome Medicine · doi:10.1186/gm34 · Cited by 136
3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish”
Choi, S. H., Kim, Y. H., Quinti, L., Tanzi, R. E., & Kim, D. Y. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0139-7 · Cited by 132
“However, there is no clear therapeutic option for AD patients yet, except for some symptomatic reliefs [3, 5, 6].”
BackgroundSelf-citationTau‐targeted treatment strategies in Alzheimer's disease
Götz, J., Ittner, A., & Ittner, L. M. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01713.x · Cited by 129
“In three genes, autosomal-dominant mutations have been iden- tified, in APP itself, as well as in presenilin 1 (PSEN1) and 2 (PSEN2) that both encode a component of the enzyme complex that is required to generate Ab (Bertram and Tanzi, 2008).”
BackgroundHaure-Mirande, J.-V., Audrain, M., Fanutza, T., Kim, S. H., Klein, W. L., Glabe, C., Readhead, B., Dudley, J. T., Blitzer, R. D., Wang, M., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1737-3 · Cited by 127
“Oxidative stress may also promote production and deposition of Aβ and formation of neurofibrillary tangles [8, 14, 20, 46, 53].”
BackgroundModeling Alzheimer's disease with human induced pluripotent stem (iPS) cells
Mungenast, A. E., Siegert, S., & Tsai, L.-H. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.11.010 · Cited by 127
“Individuals with one APOE4 allele are three to four times more likely to develop AD than those without APOE4 alleles, an odds ratio that is by far the highest out of any AD risk gene (Bertram and Tanzi, 2008; Corder et al., 1993).”
BackgroundThe role of amyloid oligomers in neurodegenerative pathologies
Wells, C., Brennan, S. E., Keon, M., & Ooi, L. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.03.113 · Cited by 137
Interactome mapping suggests new mechanistic details underlying Alzheimer's disease
Soler-López, M., Zanzoni, A., Lluís, R., Stelzl, U., & Aloy, P. (2011) · Genome Research · doi:10.1101/gr.114280.110 · Cited by 124
Tayeb, H. O., Murray, E. D., Price, B. H., & Tarazi, F. I. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.789856 · Cited by 119
“All the known inherited forms of AD are due to mutations in genes encoding key proteins in amyloid metabolism, including the amyloid precursor protein (the origin protein of amyloid species), and presenilin 1 and presenilin 2 proteins (components of the g-secretase protease complex) [4].”
Connectomic Intermediate Phenotypes for Psychiatric Disorders
Fornito, A., & Bullmore, E. T. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00032 · Cited by 118
“25 (Bertram and Tanzi, 2008).”
BackgroundInfluentialThe role of the blood–CNS barrier in CNS disorders and their treatment
Palmer, A. M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.029 · Cited by 117
Grimm, M. O. W., Grösgen, S., Riemenschneider, M. J., Tanila, H., Grimm, H. S., & Hartmann, T. (2011) · Journal of Chromatography A · doi:10.1016/j.chroma.2011.07.073 · Cited by 129
Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease
Penzes, P., & VanLeeuwen, J.-E. (2011) · Brain Research Reviews · doi:10.1016/j.brainresrev.2011.01.003 · Cited by 114
Shoair, O. A., Grasso, M., Lahaye, L. A., Daniel, R., Biddle, C. J., & Slattum, P. W. (2015) · Journal of Anaesthesiology Clinical Pharmacology · doi:10.4103/0970-9185.150530 · Cited by 116
“APOE4 genotype has been associated consistently with a threefold or greater increase in the risk of Alzheimer’s disease.[19] However, the mechanism by which APOE4 plays a role in the development of POCD is still unclear.”
BackgroundThe neuritic plaque facilitates pathological conversion of tau in an Alzheimer’s disease mouse model
Li, T., Braunstein, K. E., Zhang, J., Lau, A., Sibener, L., Deeble, C., & Wong, P. C. (2016) · Nature Communications · doi:10.1038/ncomms12082 · Cited by 114
“Genetic studies of early-onset familial AD (fAD), which accounts for 5–10% of cases of AD 6,7 , have fuelled the notion that abnormal accumulation of A b in the brain would trigger the aggregation of tau leading to neurodegeneration and dementia 2,8 .”
Metadata
- Authors
- Bertram, L., & Tanzi, R. E.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bertram, Lars
- Venue
- Nature Reviews Neuroscience
- Published
- 2008-10
- Volume
- 9
- Issue
- 10
- Pages
- 768-778
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2018342879
- Cited by
- 747
- References
- 113
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 25 · 2023: 21 · 2022: 33 · 2021: 26 · 2020: 29 · 2019: 34 · 2018: 41 · 2017: 46 · 2016: 37 · 2015: 41 · 2014: 46 · 2013: 59 · 2012: 62
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (5R01-AG23667, R01AG023667)
- National Institute of Mental Health (5R37MH60009, R37MH060009)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease genetics, genetic risk factors, candidate genes, meta-analysis, amyloid precursor protein, presenilin 1, presenilin 2, apolipoprotein E, early-onset familial Alzheimer's disease, late-onset Alzheimer's disease, disease pathology, metabolic pathways
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain Chemistry, Humans, Mutation, Risk Factors, Meta-Analysis as Topic, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Presenilins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.